Role of Embolization of Thyroid Arteries as a Treatment for Different Thyroid Disorders
Role of Selective Embolization of Thyroid Arteries (SETA) as an Adjunctive or Definitive Treatment for Different Thyroid Disorders
1 other identifier
interventional
20
0 countries
N/A
Brief Summary
To investigate the safety and efficacy of selective embolization of thyroid arteries (SETA) as adjunctive or definitive treatment in different thyroid disorders
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2024
Typical duration for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 12, 2024
CompletedFirst Posted
Study publicly available on registry
August 5, 2024
CompletedStudy Start
First participant enrolled
August 10, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 9, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2026
August 5, 2024
August 1, 2024
1.9 years
July 12, 2024
August 1, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
To investigate the safety of selective embolization of thyroid arteries (SETA) as adjunctive or definitive treatment in different thyroid disorders
Safety measured according to incidence of major and minor complications compared to thyroidectomy.
Up to 12 months follow up after embolization
To investigate the efficacy of selective embolization of thyroid arteries (SETA) as adjunctive or definitive treatment in different thyroid disorders
in hyperfunctiong (toxic) disorders Efficacy measured according to thyroid profile levels in certain time interval post procedure, every 3 months time interval and rate of hyper functioning recurrence in comparison to thyroidectomy. In diffuse or nodular goiter we measure efficacy by percentage of size reduction post procedure in comparison to primary size just before procedure
Up to 12 months follow up after embolization
Study Arms (2)
graves disease patients
ACTIVE COMPARATORmultinodular goiter
ACTIVE COMPARATORInterventions
selective embolization of thyroid arteries
Eligibility Criteria
You may qualify if:
- A- diffuse and Nodular goiter:
- B-Toxic goiter:
- C-Thyroid cancer:
You may not qualify if:
- A. Significant bleeding diathesis. B. Contraindication for contrast media (renal impairment or allergy). C. Severe atherosclerotic disease prevent arterial catheterization. D. Refusal of signing a consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Who Masked
- PARTICIPANT, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- assistant lecturer
Study Record Dates
First Submitted
July 12, 2024
First Posted
August 5, 2024
Study Start
August 10, 2024
Primary Completion (Estimated)
July 9, 2026
Study Completion (Estimated)
July 30, 2026
Last Updated
August 5, 2024
Record last verified: 2024-08